Your cart is empty now.
Report copyright infringement
by Arnold Melman (Author), Rosemary Newnham (Author)
Men who have completed prostate cancer treatment often find themselves facing new challenges and setbacks that do not necessarily recede along with the cancer. Many books endeavor to explain the different types of prostate cancer treatments, but most conclude once a treatment choice has been made, offering readers little in the way of guidance through the challenges of the post-treatment period.
Arnold Melman, MD, is the Professor and Chairman of the Department of Urology. Dr. Melman is a 1966 graduate of the University of Rochester School of Medicine. He did his internship and assistant residency in surgery in that institution's Strong Memorial Hospital. In 1968 to 1970 he was a clinical fellow in Urology in the NICHD's Gerontology Research Center. Dr. Melman did his Urology training at UCLA from 1970 to 1974. He has been an assistant and associate Professor of Urology at the Indiana University School of Medicine and Chief of Urology at Indiana University School of Medicine and Chief of Urology at the Indianapolis VA Hospital. After returning to New York City in 1979, he became Professor of Urology at the Mount Sinai School of Medicine and in 1986 Chief of Urology at the Beth Israel Medical Center. He assumed his present role as Chairman of the Department of Urology in 1988. He is a busy clinical surgeon with an interest in Radical Perineal Prostatectomy, ReconstructiveSurgery, Microvascular Surgery. He has a subspecialty interest in basic research and the diagnosis and treatment of male sexual dysfunction. Under his direction, numerous basic research projects are being conducted at the Albert Einstein College of Medicine Urological Research Laboratory. Dr. Melman has published more than 150 scientific articles and book chapters. In 1997 Dr. Melman was the president for the Society for the Study of Impotence. He's the Principal Investigator on an NIH grant designed to evaluate basic mechanisms of erectile physiology and was co-editor of the International Journal of Impotence Research. Dr. Melman is the past chairman of the FDA's Gastroenterology and Urology devices panel and is currently a voting member of the panel. He has been a reviewer at the National Institute of Health's Study Section for Urology grants for the past two years. Dr. Melman is the Principal Investigator on several clinical trials of new medications and treatment modalities. He has been granted patents on several new urological devices. Dr. Melman is a co-developer of the use of gene transfer for the therapy of smooth muscle diseases of the genito urinary systems.In addition, Dr. Melman, along with Dr. George J. Christ, Ph.D., is a directing member of Ion Channel Innovations [http: //www.ionchannelinnovations.com/], a development stage biotechnology company formed to develop Ion Channel Therapy (ICT), an innovative gene transfer solution expected to be safe and effective for the long-term treatment of erectile dysfunction (ED), urinary incontinence (UI, urinary urgency, frequency and incontinence related to overactive bladder (OAB)), and potentially other smooth muscle diseases.
Guaranteed safe checkout:
There are 0 Items In Your Cart.
Added to cart successfully!
Total Price: $0.00